FDA
-
-
-
-
-
-
-
ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care
-
-
-
-
-
-
-
ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA
-
-
-
-
-
-
-
ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results
-
-
-
-
-
-
-
Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024
-
-
-
-
-
-
-
ENDRA Life Sciences Announces Reverse Stock Split
-
-
-
-
-
-
-
New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System
-
-
-
-
-
-
-
ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA
-
322,255 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

